ABBV

SEC source: 0001415889-25-006024 · form4-02282025_050201.xml · nonDerivative · entry 4

RICHMOND TIMOTHY J. · CIK 0001563523 · EVP, CHIEF HR OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 66,494

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001415889-25-006024 · form4-02282025_050201.xml · nonDerivative · entry 3

RICHMOND TIMOTHY J. · CIK 0001563523 · EVP, CHIEF HR OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 44,284

F1 · shares: This sale was executed pursuant to a Rule 10b5-1 plan that was entered into by the Reporting Person on November 27, 2024.

F4 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $203.58 to $203.65, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001415889-25-006024 · form4-02282025_050201.xml · nonDerivative · entry 2

RICHMOND TIMOTHY J. · CIK 0001563523 · EVP, CHIEF HR OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 45,810

F1 · shares: This sale was executed pursuant to a Rule 10b5-1 plan that was entered into by the Reporting Person on November 27, 2024.

F3 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $202.58 to $203.56, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001415889-25-006024 · form4-02282025_050201.xml · nonDerivative · entry 1

RICHMOND TIMOTHY J. · CIK 0001563523 · EVP, CHIEF HR OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 50,591

F1 · shares: This sale was executed pursuant to a Rule 10b5-1 plan that was entered into by the Reporting Person on November 27, 2024.

F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $201.58 to $202.45, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001415889-25-006025 · form4-02282025_050204.xml · derivative · entry 6

Buckbee Kevin K · CIK 0001968528 · SVP, CONTROLLER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,794

Underlying: Common Stock · 6,522 shares

Expires 2031-02-17

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · security: Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3.

SEC source: 0001415889-25-006025 · form4-02282025_050204.xml · derivative · entry 5

Buckbee Kevin K · CIK 0001968528 · SVP, CONTROLLER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,373

Underlying: Common Stock · 9,738 shares

Expires 2030-02-19

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · security: Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3.

SEC source: 0001415889-25-006025 · form4-02282025_050204.xml · nonDerivative · entry 4

Buckbee Kevin K · CIK 0001968528 · SVP, CONTROLLER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,496

F1 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $203.39 to $203.48, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F2 · balance_after: The reporting person transferred 1,150 shares of common stock to his former spouse pursuant to a domestic relations order since his last ownership report and has ceased to be the beneficial owner of such shares.

SEC source: 0001415889-25-006025 · form4-02282025_050204.xml · nonDerivative · entry 3

Buckbee Kevin K · CIK 0001968528 · SVP, CONTROLLER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 28,906

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001415889-25-006025 · form4-02282025_050204.xml · nonDerivative · entry 2

Buckbee Kevin K · CIK 0001968528 · SVP, CONTROLLER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 22,384

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001415889-25-006025 · form4-02282025_050204.xml · nonDerivative · entry 1

Buckbee Kevin K · CIK 0001968528 · SVP, CONTROLLER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,646

SEC source: 0001415889-25-005291 · form4-02242025_050201.xml · nonDerivative · entry 2

Siatis Perry C · CIK 0001951400 · EVP, GC AND SECRETARY

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 22,381

F1 · shares: This sale was executed pursuant to a Rule 10b5-1 plan that was entered into by the Reporting Person on November 19, 2024.

F3 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $197.88 to $198.65, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001415889-25-005291 · form4-02242025_050201.xml · nonDerivative · entry 1

Siatis Perry C · CIK 0001951400 · EVP, GC AND SECRETARY

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 26,375

F1 · shares: This sale was executed pursuant to a Rule 10b5-1 plan that was entered into by the Reporting Person on November 19, 2024.

F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $196.87 to $197.7, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001415889-25-004455 · form4-02182025_050201.xml · derivative · entry 5

GONZALEZ RICHARD A · CIK 0001239127 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 65,104

Underlying: Common Stock · 65,104 shares

Expires 2035-02-12

F5 · security: Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 21,702 on February 13, 2026, 21,701 on February 13, 2027, and 21,701 on February 13, 2028.

F5 · derivative.exercise_date: Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 21,702 on February 13, 2026, 21,701 on February 13, 2027, and 21,701 on February 13, 2028.

SEC source: 0001415889-25-004455 · form4-02182025_050201.xml · nonDerivative · entry 4

GONZALEZ RICHARD A · CIK 0001239127 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 560,766

F4 · shares: Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 15, 2024. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2025.

SEC source: 0001415889-25-004455 · form4-02182025_050201.xml · nonDerivative · entry 3

GONZALEZ RICHARD A · CIK 0001239127 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 533,380

F3 · shares: Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 16, 2023. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2025.

SEC source: 0001415889-25-004455 · form4-02182025_050201.xml · nonDerivative · entry 2

GONZALEZ RICHARD A · CIK 0001239127 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 503,082

F2 · shares: Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 17, 2022. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2025.

SEC source: 0001415889-25-004455 · form4-02182025_050201.xml · nonDerivative · entry 1

GONZALEZ RICHARD A · CIK 0001239127 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 469,874

F1 · shares: Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 17, 2022. The award is subject to performance-vesting restrictions based on earnings per share and relative total shareholder return. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2025.

SEC source: 0001415889-25-004456 · form4-02182025_050203.xml · derivative · entry 5

Michael Robert A. · CIK 0001699914 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 83,333

Underlying: Common Stock · 83,333 shares

Expires 2035-02-12

F5 · security: Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 27,778 on February 13, 2026, 27,778 on February 13, 2027, and 27,777 on February 13, 2028.

F5 · derivative.exercise_date: Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 27,778 on February 13, 2026, 27,778 on February 13, 2027, and 27,777 on February 13, 2028.

SEC source: 0001415889-25-004456 · form4-02182025_050203.xml · nonDerivative · entry 4

Michael Robert A. · CIK 0001699914 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 160,007

F4 · shares: Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 15, 2024. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2025.

SEC source: 0001415889-25-004456 · form4-02182025_050203.xml · nonDerivative · entry 3

Michael Robert A. · CIK 0001699914 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 145,553

F3 · shares: Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 16, 2023. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2025.

SEC source: 0001415889-25-004456 · form4-02182025_050203.xml · nonDerivative · entry 2

Michael Robert A. · CIK 0001699914 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 133,523

F2 · shares: Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 17, 2022. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2025.

SEC source: 0001415889-25-004456 · form4-02182025_050203.xml · nonDerivative · entry 1

Michael Robert A. · CIK 0001699914 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 123,377

F1 · shares: Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 17, 2022. The award is subject to performance-vesting restrictions based on earnings per share and relative total shareholder return. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2025.

SEC source: 0001415889-25-004457 · form4-02182025_050205.xml · derivative · entry 5

Donoghoe Nicholas · CIK 0001762951 · EVP, CHIEF BUS/STRAT OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 23,437

Underlying: Common Stock · 23,437 shares

Expires 2035-02-12

F5 · security: Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 7,813 on February 13, 2026, 7,812 on February 13, 2027, and 7,812 on February 13, 2028.

F5 · derivative.exercise_date: Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 7,813 on February 13, 2026, 7,812 on February 13, 2027, and 7,812 on February 13, 2028.

SEC source: 0001415889-25-004457 · form4-02182025_050205.xml · nonDerivative · entry 4

Donoghoe Nicholas · CIK 0001762951 · EVP, CHIEF BUS/STRAT OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 81,248

F4 · shares: Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 15, 2024. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2025.

SEC source: 0001415889-25-004457 · form4-02182025_050205.xml · nonDerivative · entry 3

Donoghoe Nicholas · CIK 0001762951 · EVP, CHIEF BUS/STRAT OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 76,074

F3 · shares: Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 16, 2023. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2025.

SEC source: 0001415889-25-004457 · form4-02182025_050205.xml · nonDerivative · entry 2

Donoghoe Nicholas · CIK 0001762951 · EVP, CHIEF BUS/STRAT OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 71,440

F2 · shares: Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 17, 2022. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2025.

SEC source: 0001415889-25-004457 · form4-02182025_050205.xml · nonDerivative · entry 1

Donoghoe Nicholas · CIK 0001762951 · EVP, CHIEF BUS/STRAT OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 66,920

F1 · shares: Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 17, 2022. The award is subject to performance-vesting restrictions based on earnings per share and relative total shareholder return. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2025.

SEC source: 0001415889-25-004458 · form4-02182025_050207.xml · derivative · entry 5

Reents Scott T · CIK 0001937048 · EVP, CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 27,343

Underlying: Common Stock · 27,343 shares

Expires 2035-02-12

F5 · security: Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 9,115 on February 13, 2026, 9,114 on February 13, 2027, and 9,114 on February 13, 2028.

F5 · derivative.exercise_date: Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 9,115 on February 13, 2026, 9,114 on February 13, 2027, and 9,114 on February 13, 2028.

SEC source: 0001415889-25-004458 · form4-02182025_050207.xml · nonDerivative · entry 4

Reents Scott T · CIK 0001937048 · EVP, CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 40,194

F4 · shares: Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 15, 2024. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2025.

SEC source: 0001415889-25-004458 · form4-02182025_050207.xml · nonDerivative · entry 3

Reents Scott T · CIK 0001937048 · EVP, CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 32,586

F3 · shares: Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 16, 2023. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2025.

SEC source: 0001415889-25-004458 · form4-02182025_050207.xml · nonDerivative · entry 2

Reents Scott T · CIK 0001937048 · EVP, CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 23,674

F2 · shares: Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 17, 2022. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2025.

SEC source: 0001415889-25-004458 · form4-02182025_050207.xml · nonDerivative · entry 1

Reents Scott T · CIK 0001937048 · EVP, CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 21,276

F1 · shares: Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 17, 2022. The award is subject to performance-vesting restrictions based on earnings per share and relative total shareholder return. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2025.

SEC source: 0001415889-25-004459 · form4-02182025_050209.xml · derivative · entry 5

RICHMOND TIMOTHY J. · CIK 0001563523 · EVP, CHIEF HR OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 22,916

Underlying: Common Stock · 22,916 shares

Expires 2035-02-12

F5 · security: Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 7,639 on February 13, 2026, 7,639 on February 13, 2027, and 7,638 on February 13, 2028.

F5 · derivative.exercise_date: Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 7,639 on February 13, 2026, 7,639 on February 13, 2027, and 7,638 on February 13, 2028.

SEC source: 0001415889-25-004459 · form4-02182025_050209.xml · nonDerivative · entry 4

RICHMOND TIMOTHY J. · CIK 0001563523 · EVP, CHIEF HR OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 51,991

F4 · shares: Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 15, 2024. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2025.

SEC source: 0001415889-25-004459 · form4-02182025_050209.xml · nonDerivative · entry 3

RICHMOND TIMOTHY J. · CIK 0001563523 · EVP, CHIEF HR OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 44,993

F3 · shares: Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 16, 2023. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2025.

SEC source: 0001415889-25-004459 · form4-02182025_050209.xml · nonDerivative · entry 2

RICHMOND TIMOTHY J. · CIK 0001563523 · EVP, CHIEF HR OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 39,201

F2 · shares: Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 17, 2022. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2025.

SEC source: 0001415889-25-004459 · form4-02182025_050209.xml · nonDerivative · entry 1

RICHMOND TIMOTHY J. · CIK 0001563523 · EVP, CHIEF HR OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 31,823

F1 · shares: Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 17, 2022. The award is subject to performance-vesting restrictions based on earnings per share and relative total shareholder return. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2025.

SEC source: 0001415889-25-004460 · form4-02182025_050212.xml · derivative · entry 7

SALEKI-GERHARDT AZITA · CIK 0001563545 · EVP, CHIEF OPERATIONS OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,000

Underlying: Common Stock · 25,000 shares

Expires 2035-02-12

F7 · security: Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 8,334 on February 13, 2026, 8,333 on February 13, 2027, and 8,333 on February 13, 2028.

F7 · derivative.exercise_date: Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 8,334 on February 13, 2026, 8,333 on February 13, 2027, and 8,333 on February 13, 2028.

SEC source: 0001415889-25-004460 · form4-02182025_050212.xml · nonDerivative · entry 4

SALEKI-GERHARDT AZITA · CIK 0001563545 · EVP, CHIEF OPERATIONS OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 232,846

F4 · shares: Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 15, 2024. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2025.

SEC source: 0001415889-25-004460 · form4-02182025_050212.xml · nonDerivative · entry 3

SALEKI-GERHARDT AZITA · CIK 0001563545 · EVP, CHIEF OPERATIONS OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 225,772

F3 · shares: Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 16, 2023. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2025.

SEC source: 0001415889-25-004460 · form4-02182025_050212.xml · nonDerivative · entry 2

SALEKI-GERHARDT AZITA · CIK 0001563545 · EVP, CHIEF OPERATIONS OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 219,712

F2 · shares: Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 17, 2022. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2025.

SEC source: 0001415889-25-004460 · form4-02182025_050212.xml · nonDerivative · entry 1

SALEKI-GERHARDT AZITA · CIK 0001563545 · EVP, CHIEF OPERATIONS OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 212,334

F1 · shares: Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 17, 2022. The award is subject to performance-vesting restrictions based on earnings per share and relative total shareholder return. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2025.

SEC source: 0001415889-25-004461 · form4-02182025_050214.xml · derivative · entry 5

Siatis Perry C · CIK 0001951400 · EVP, GC AND SECRETARY

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 21,875

Underlying: Common Stock · 21,875 shares

Expires 2035-02-12

F5 · security: Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 7,292 on February 13, 2026, 7,292 on February 13, 2027, and 7,291 on February 13, 2028.

F5 · derivative.exercise_date: Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 7,292 on February 13, 2026, 7,292 on February 13, 2027, and 7,291 on February 13, 2028.

SEC source: 0001415889-25-004461 · form4-02182025_050214.xml · nonDerivative · entry 4

Siatis Perry C · CIK 0001951400 · EVP, GC AND SECRETARY

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 28,159

F4 · shares: Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 15, 2024. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2025.

SEC source: 0001415889-25-004461 · form4-02182025_050214.xml · nonDerivative · entry 3

Siatis Perry C · CIK 0001951400 · EVP, GC AND SECRETARY

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 22,529

F3 · shares: Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 16, 2023. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2025.

SEC source: 0001415889-25-004461 · form4-02182025_050214.xml · nonDerivative · entry 2

Siatis Perry C · CIK 0001951400 · EVP, GC AND SECRETARY

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,737

F2 · shares: Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 17, 2022. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2025.

SEC source: 0001415889-25-004461 · form4-02182025_050214.xml · nonDerivative · entry 1

Siatis Perry C · CIK 0001951400 · EVP, GC AND SECRETARY

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,893

F1 · shares: Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 17, 2022. The award is subject to performance-vesting restrictions based on earnings per share and relative total shareholder return. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2025.

SEC source: 0001415889-25-004462 · form4-02182025_050216.xml · derivative · entry 6

Stewart Jeffrey Ryan · CIK 0001761675 · EVP, CHIEF COMMERCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 33,854

Underlying: Common Stock · 33,854 shares

Expires 2035-02-12

F6 · security: Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 11,285 on February 13, 2026, 11,285 on February 13, 2027, and 11,284 on February 13, 2028.

F6 · derivative.exercise_date: Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 11,285 on February 13, 2026, 11,285 on February 13, 2027, and 11,284 on February 13, 2028.

SEC source: 0001415889-25-004462 · form4-02182025_050216.xml · nonDerivative · entry 4

Stewart Jeffrey Ryan · CIK 0001761675 · EVP, CHIEF COMMERCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 106,592

F4 · shares: Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 15, 2024. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2025.

SEC source: 0001415889-25-004462 · form4-02182025_050216.xml · nonDerivative · entry 3

Stewart Jeffrey Ryan · CIK 0001761675 · EVP, CHIEF COMMERCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 97,160

F3 · shares: Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 16, 2023. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2025.